OTCMKTS:RZLTD Rezolute (RZLTD) Stock Price, News & Analysis $9.00 +0.58 (+6.89%) As of 10/15/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Rezolute Stock (OTCMKTS:RZLTD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rezolute alerts:Sign Up Key Stats Today's Range$8.47▼$9.0450-Day Range$5.81▼$9.3452-Week Range$16.00▼$24.05Volume1.36 million shsAverage Volume4,788 shsMarket Capitalization$75.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Rezolute, Inc., trading on the OTC Markets under the symbol RZLTD, is a clinical-stage biopharmaceutical company based in San Diego, California. It focuses on the discovery and development of allosteric modulators for the treatment of rare metabolic and endocrine disorders. Leveraging its proprietary Native Protein Functional Modulators (NPFM) platform, Rezolute aims to fine-tune native protein function to restore physiological balance in patients with hormone resistance syndromes and enzyme deficiency diseases. The company’s lead program, RZ358, is an investigational allosteric modulator of the insulin receptor for congenital hyperinsulinism (CHI), a rare genetic disorder characterized by excessive insulin secretion and persistent hypoglycemia. Rezolute is advancing RZ358 through clinical trials designed to assess safety, tolerability, pharmacokinetics, and efficacy in reducing hypoglycemic events. In parallel, Rezolute is developing RZ402, a small molecule activator of phenylalanine hydroxylase for phenylketonuria (PKU), supported by preclinical data demonstrating its ability to enhance enzyme function and lower toxic phenylalanine levels. Under the leadership of President and CEO Siddarth Lehal, Rezolute collaborates with academic research centers, patient advocacy organizations, and clinical research networks to conduct trials across the United States and Europe. Although the company is yet to secure regulatory approval for its pipeline candidates, its precision-driven approach and focus on high unmet medical needs position Rezolute as a potential innovator in the specialty biopharmaceutical sector.AI Generated. May Contain Errors. Read More Receive RZLTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RZLTD Stock News HeadlinesRezolute (RZLT) Earnings Dates & ReportsNovember 9, 2023 | investing.comXilio Development Inc (XLO)September 3, 2023 | investing.comTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-changing system designed to replace income taxes and send direct payouts to everyday Americans. More than $1 TRILLION is expected to be distributed... and YOU could be eligible to claim a massive check.October 16 at 2:00 AM | Angel Publishing (Ad)Systems Ltd.August 9, 2023 | forbes.comStonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye DiseaseJune 1, 2023 | benzinga.comAnalysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Jazz Pharmaceuticals (JAZZ)May 15, 2023 | markets.businessinsider.comRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressMay 12, 2023 | finanznachrichten.deRezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressMay 11, 2023 | finance.yahoo.comSee More Headlines RZLTD Stock Analysis - Frequently Asked Questions How have RZLTD shares performed this year? Rezolute's stock was trading at $4.96 at the start of the year. Since then, RZLTD stock has increased by 81.5% and is now trading at $9.00. How do I buy shares of Rezolute? Shares of RZLTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:RZLTD CIKN/A Webwww.rezolutebio.com Phone650 206 4507FaxN/AEmployees23Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.33 million Net MarginsN/A Pretax MarginN/A Return on Equity-153.46% Return on Assets-111.71% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book7.26Miscellaneous Outstanding Shares8,418,000Free FloatN/AMarket Cap$75.76 million OptionableNot Optionable Beta4.63 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:RZLTD) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredWhite House Letter Reveals “MAGA’s Master Plan”If you thought tariffs were big news, the next phase of MAGA’s economic plan could be far more transformative ...StocksToTrade | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.